Gilead Sciences Buy or Sell Recommendation

Macroaxis provides Gilead Sciences Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Gilead Sciences positions. The advice algorithm takes into account all of Gilead Sciences Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Gilead Sciences buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Gilead Sciences Inc -- USA Stock  

USD 72.82  0.36  0.5%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences Inc is 'Cautious Hold'.
For the selected time horizon Gilead Sciences Inc has a mean deviation of 0.8473, semi deviation of 0.0, standard deviation of 1.05, variance of 1.1, downside variance of 0.0 and semi variance of 0.0
Macroaxis provides unbiased buy or sell recommendations on Gilead Sciences that should be used to complement current analysts and expert consensus on Gilead Sciences Inc. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences Inc is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences Inc has Price to Earning of 7.87 times, we strongly advise you confirm Gilead Sciences Inc market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return0.44Value At Risk2.33
Potential Upside1.03Standard Deviation1.05
 Return Density 

Institutional Investors

Security TypeSharesValue
Blackrock IncCommon Shares102.2 M8.3 B
Vanguard Group IncCommon Shares94.5 M7.7 B
State Street CorpCommon Shares55.4 M4.5 B
Bank Of New York Mellon CorpCommon Shares30.1 M2.4 B
Fmr LlcCommon Shares27.7 M2.2 B
Capital Research Global InvestorsCommon Shares21.9 M1.8 B
Parnassus InvestmentsCommon Shares18.7 M1.5 B
Susquehanna International Group LlpPut Options10.5 M853.9 M

Gilead Sciences Greeks

Alpha over DOW
βBeta against DOW=0.2
Overall volatility
 IrInformation ratio =0.46

Gilead Sciences Volatility Alert

Gilead Sciences Inc exhibits very low volatility with skewness of -0.3 and kurtosis of -0.66. However, we advise investors to further study Gilead Sciences Inc technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Gilead Sciences to competition
FundamentalsGilead SciencesPeer Average
Return On Equity62.19 % (15.17) %
Return On Asset19.03 % (15.64) %
Profit Margin42.9 % (5.5) %
Operating Margin58.96 % (10.91) %
Current Valuation99.29 B152.14 B
Shares Outstanding1.31 B1.43 B
Shares Owned by Insiders0.69 % 6.91 %
Shares Owned by Institutions79.54 % 18.37 %
Number of Shares Shorted16.84 M3.24 M
Price to Earning7.87 times40.69 times
Price to Book4.17 times14.44 times
Price to Sales3.32 times17.81 times
Revenue28.47 B9.85 B
Gross Profit26.13 B21.75 B
EBITDA17.97 B1.41 B
Net Income12.21 B517.71 M
Cash and Equivalents21.61 B3.89 B
Cash per Share16.55 times5.17 times
Total Debt26.3 B7.36 B
Debt to Equity113.8 % 0.72 %
Current Ratio3.37 times3.3 times
Book Value Per Share17.36 times13.64 times
Cash Flow from Operations14.01 B1.25 B
Short Ratio2.17 times2.09 times
Earnings Per Share9.21 times2.3 times
Price to Earnings To Growth(0.67) times1.22 times
Number of Employees8 K10.67 K
Market Capitalization94.63 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B
Cautious Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Bona fide gift to Norbert Bischofberger of 10000 shares of Gilead Sciences subject to Section 16 [view details]
Risk Adjusted Performance(0.14)
Market Risk Adjusted Performance2.3
Mean Deviation0.8473
Coefficient Of Variation(239.77)
Standard Deviation1.05
Information Ratio(0.46)
Jensen Alpha(0.44)
Total Risk Alpha(0.55)
Treynor Ratio2.29
Maximum Drawdown3.47
Value At Risk(2.33)
Potential Upside1.03

Current Valuation

Gilead Sciences Current Valuation Analysis
Gilead Sciences Inc is rated # 2 in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is currently estimated at about 345.64 Billion. Gilead Sciences totals roughly 99.29 Billion in current valuation claiming about 29% of equities listed under Pharmaceuticals And Biosciences industry.